West Virginia University Logo

Disease Site: Genitourinary Cancers

9 protocol(s) meet the specified criteria

  • 2018-01Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors
  • 4010-01-001A Phase I Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors.
  • APL-101-01Phase 1 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Advanced Solid Tumors and c-Met Dysregulation
  • EAY131Molecular Analysis for Therapy Choice (MATCH)
  • NRG-GU002Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prosatectomy with or without Adjuvant Docetaxel.
  • NRG-GU005Phase III IGRT and SBRT versus IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
  • NRG-GU006A Phase II, Double-Blinded, Placebo Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-androgen Therapy With Apalutamide in Recurrent Prostate Cancer
  • RTOG0924Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
  • WVU021119Evaluation of the Epigenetic Effects of Circulating DNA Methyltransferases and Histone Deacetylase Levels to Predict Toxicity from Radiation Therapy